Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159056 | 0.86 | ALDH1A1 (0.56) | PTPN7ALDH1A1ALOX15MCL1HTT | |
| SCHEMBL535592 | 0.84 | MCL1 (0.56) | ALDH1A1PDE2APDE3BPDE3AP2RY12 | |
| SCHEMBL534453 | 0.81 | ALDH1A1 (0.51) | PTPN7ALDH1A1ALOX15MCL1HTT | |
| SCHEMBL14816245 | 0.81 | KDM4E (0.60) | ALDH1A1PDE3BPDE3AP2RY12ALOX15 | |
| SCHEMBL5267380 | 0.81 | ALDH1A1 (0.68) | ALDH1A1ALOX15MCL1HTTPPARG | |
| Malonic Acid SCHEMBL11881627 | 0.81 | ALDH1A1 (0.60) | ALDH1A1ALOX15MCL1HTTMAPT | |
| SCHEMBL19924517 | 0.81 | ALDH1A1 (0.64) | ALDH1A1ALOX15MCL1HTTPPARG | |
| SCHEMBL25640 | 0.80 | PTPN7 (1.00) | PTPN7ALDH1A1ALOX15HTTPPARG | |
| SCHEMBL29367022 | 0.80 | PTPN7 (1.00) | PTPN7ALDH1A1ALOX15HTTPPARG | |
| SCHEMBL14273081 | 0.79 | PTPN7 (0.63) | PTPN7ALOX15MIFMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| CN-108203438-B | Fused imidazole compounds having indoleamine 2,3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-03-31 | — | — | US | disclosed |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3560928-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
| US-6291432-B1 | (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. | JAPAN ENERGY CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0900566-A1 | NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS | JAPAN ENERGY CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | PTPN7 3491/4885ALDH1A1 735/4885PDE2A 2731/4885 |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | IDO1, IDO2, INMT | PTPN7 3071/4885ALDH1A1 376/4885PDE2A 2157/4885 |
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | CRBN, CLNS1A, ADRM1 | PTPN7 1285/4885ALDH1A1 2347/4885PDE2A 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.